Aurora Financial JournalPharma Equity Group A/S (PEGA.CO)
Nasdaq Copenhagen · Financial statements, TTM figures and earnings dates
In fiscal year 2025 (ended December 31, 2025), Pharma Equity Group A/S reported revenue of DKK 0 and net income of −DKK 25.4M. Annual financial statements are available for fiscal years 2022 to 2025, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| DKK | FY2025 2025-12-31 | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | DKK 0 | DKK 0 | DKK 0 | DKK 0 |
| Gross profit | DKK 0 | DKK 0 | DKK 0 | DKK 0 |
| Operating income | −DKK 17.2M | −DKK 21.3M | −DKK 20.6M | −DKK 11.3M |
| Net income | −DKK 25.4M | −DKK 40.6M | −DKK 24.3M | −DKK 9.4M |
| Diluted EPS | −DKK 2.00 | −DKK 2.00 | −DKK 0.02 | −DKK 0.01 |
| Cash flow | ||||
| Operating cash flow | −DKK 17.7M | −DKK 22.9M | −DKK 16.6M | −DKK 8.3M |
| Capital expenditure | DKK 11.0K | DKK 0 | DKK 73.0K | DKK 0 |
| Free cash flow | −DKK 17.7M | −DKK 22.9M | −DKK 16.7M | −DKK 8.3M |
| Balance sheet | ||||
| Cash and equivalents | DKK 498.0K | DKK 4.2M | DKK 4.2M | DKK 2.8M |
| Total assets | DKK 38.9M | DKK 49.4M | DKK 67.7M | DKK 21.5M |
| Total liabilities | DKK 13.4M | DKK 16.7M | DKK 42.4M | DKK 2.6M |
| Shareholders' equity | DKK 25.5M | DKK 32.7M | DKK 25.3M | DKK 5.0M |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in DKK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full PEGA.CO page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open PEGA.CO financials →